TRPV1 and metabolic dysfunction-associated steatotic liver disease: Although CAP’s anti-obesity and lipid-lowering effects via TRPV1 activation have been demonstrated [17], its therapeutic potential against MASLD and associated insulin resistance remains poorly defined.